NQO1*2 polymorphism and response to treatment in patients with multiple myeloma

Leukemia Research

Volumn 31, Issue 8, 2007, Pages 1029-1030

  Buda, Gabriele ^a   Maggini, Valentina ^a   Galimberti, Sara ^a   Barale, Roberto ^a   Rossi, Anna Maria ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Chemotherapy; Multiple myeloma; NQO1

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; VINCRISTINE; ANTINEOPLASTIC AGENT; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; DISEASE COURSE; DNA POLYMORPHISM; DRUG METABOLISM; EDITORIAL; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE; GENETIC POLYMORPHISM; GENETICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MULTIPLE MYELOMA; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC;

EID: 34249935733     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.01.011     Document Type: Editorial

References (3)

1. Nebert D.W., Roe A.L., Vandale S.E., Bingham E., and Oakley G.G. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 4 2 (2002) 62-70 [review]
2. *2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 31 7 (2007) 947-953
3. Lincz L.F., Scorgie F.E., Robertson R., and Enno A. Genetic variations in benzene metabolism and susceptibility to multiple myeloma. Leuk Res 31 6 (2007) 759-763